Oncternal Therapeutics Inc ONCT

NAS: ONCT | ISIN: US68236P1075 14/11/2024

1,110 USD (-2,63%)

(-2,63%) 14/11/2024

Toon enkel gratis nieuws

18 maart 2021 · Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

11 maart 2021 · Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results · Persbericht

22 februari 2021 · Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 januari 2021 · Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors · Persbericht

14 januari 2021 · Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program · Persbericht

7 januari 2021 · Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe